BridgeMD
A clinical study to investigate the efficacy of tarlatamab in people with extensive-stage small cell lung cancer (ES-SCLC) whose cancer has progressed during or after prior treatment and who have a limited health status.
EU CTIS ID: 2025-522288-13-00
What this study is testing
The primary objective of the trial is to assess the clinical efficacy of tarlatamab in terms of 12-month overall survival (OS) rate in patients with ES-SCLC and ECOG PS 2 who have previously received one line of platinum-etoposide doublet chemotherapy with an immune-checkpoint inhibitor and whose disease has progressed.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Histologically or cytologically confirmed ES-SCLC
- Previous treatment with only one line of platinum-etoposide doublet chemotherapy with immune-checkpoint inhibition for SCLC
- Progressive disease on or after the first-line treatment for SCLC
- ECOG Performance Status 2
- Age ≥18 years
- Adequate organ function
You likely can't join if
- Symptomatic CNS metastases
- Diagnosis or evidence of leptomeningeal disease or spinal cord compression
- Prior history of immune-related recurrent pneumonitis (grade ≥2)) or severe immune-mediated adverse events
- Evidence of interstitial lung disease or active, non-infectious pneumonitis
- Active autoimmune disease
- History of solid organ transplantation
See the full eligibility criteria
- Histologically or cytologically confirmed ES-SCLC
- Previous treatment with only one line of platinum-etoposide doublet chemotherapy with immune-checkpoint inhibition for SCLC
- Progressive disease on or after the first-line treatment for SCLC
- ECOG Performance Status 2
- Age ≥18 years
- Adequate organ function
- Negative pregnancy test for female participants of childbearing potential
- Written Informed Consent signed before any trial-related intervention
- Symptomatic CNS metastases
- Diagnosis or evidence of leptomeningeal disease or spinal cord compression
- Prior history of immune-related recurrent pneumonitis (grade ≥2)) or severe immune-mediated adverse events
- Evidence of interstitial lung disease or active, non-infectious pneumonitis
- Active autoimmune disease
- History of solid organ transplantation
- Presence or history of an uncontrolled viral infection
- History of other malignancy within the past 2 years
The study team makes the final eligibility decision.
Where it's taking place
- Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.